Anika Therapeutics 향후 성장

Future 기준 점검 0/6

Anika Therapeutics은 연간 수입과 매출이 각각 67.6%와 5.2% 증가할 것으로 예상되고 EPS는 연간 66.4%만큼 증가할 것으로 예상됩니다.

핵심 정보

67.6%

이익 성장률

66.36%

EPS 성장률

Biotechs 이익 성장	25.3%
매출 성장률	5.2%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	30 Apr 2026

최근 향후 성장 업데이트

Recent updates

Seeking Alpha • Apr 30

Bullish On Anika Therapeutics's Pullback As Integrity Scales

Summary Anika Therapeutics is refocusing on HA-based OA pain management and regenerative orthopedic products. The main drivers here are Monovisc, Orthovisc, and Integrity. Particularly, ANIK’s Integrity received 510(k) clearance in 2023. Recently, its revenues have more than doubled in 2025. Hyalofast and Cingal also offer interesting regulatory catalysts, but they bring FDA timing and approval risks. ANIK’s valuation seems quite cheap overall, with no financial debt and positive TTM cash flows. So, despite its inherent regulatory and execution risks, I remain bullish. Read the full article on Seeking Alpha

분석 기사 • Aug 06

Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price Following 26% Dive

NasdaqGS:ANIK 1 Year Share Price vs Fair Value Explore Anika Therapeutics's Fair Values from the Community and select...

분석 기사 • May 10

Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price

Anika Therapeutics, Inc.'s ( NASDAQ:ANIK ) price-to-sales (or "P/S") ratio of 1.4x might make it look like a strong buy...

분석 기사 • Dec 19

Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 1.4x Anika Therapeutics, Inc. ( NASDAQ:ANIK ) may be sending very bullish...

분석 기사 • Jan 30

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Key Insights Anika Therapeutics' estimated fair value is US$44.70 based on 2 Stage Free Cash Flow to Equity Anika...

분석 기사 • Aug 03

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

이익 및 매출 성장 예측

NasdaqGS:ANIK - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	134	-1	9	N/A	1
12/31/2027	127	-3	7	N/A	2
12/31/2026	119	-10	-4	N/A	2
3/31/2026	116	-11	2	6	N/A
12/31/2025	113	-10	5	11	N/A
9/30/2025	113	-14	1	8	N/A
6/30/2025	115	-13	-1	6	N/A
3/31/2025	117	-11	-4	5	N/A
12/31/2024	120	-9	-3	5	N/A
9/30/2024	86	10	-1	7	N/A
6/30/2024	98	5	1	9	N/A
3/31/2024	112	5	-4	2	N/A
12/31/2023	121	-3	-7	-2	N/A
9/30/2023	163	-25	-11	-5	N/A
6/30/2023	162	-22	-16	-9	N/A
3/31/2023	157	-22	-5	3	N/A
12/31/2022	114	2	-3	4	N/A
9/30/2022	152	-16	2	8	N/A
6/30/2022	152	-11	2	8	N/A
3/31/2022	150	-2	3	9	N/A
12/31/2021	148	4	3	8	N/A
9/30/2021	145	-6	2	7	N/A
6/30/2021	137	-13	7	10	N/A
3/31/2021	129	-27	8	10	N/A
12/31/2020	130	-24	11	13	N/A
9/30/2020	128	-4	22	24	N/A
6/30/2020	126	11	26	28	N/A
3/31/2020	125	28	27	30	N/A
12/31/2019	115	27	N/A	37	N/A
9/30/2019	112	31	N/A	34	N/A
6/30/2019	109	29	N/A	35	N/A
3/31/2019	109	30	N/A	34	N/A
12/31/2018	106	19	N/A	35	N/A
9/30/2018	108	19	N/A	32	N/A
6/30/2018	108	18	N/A	33	N/A
3/31/2018	111	20	N/A	35	N/A
12/31/2017	113	32	N/A	41	N/A
9/30/2017	113	32	N/A	40	N/A
6/30/2017	111	34	N/A	39	N/A
3/31/2017	104	31	N/A	32	N/A
12/31/2016	103	33	N/A	24	N/A
9/30/2016	106	36	N/A	34	N/A
6/30/2016	103	35	N/A	31	N/A
3/31/2016	100	34	N/A	43	N/A
12/31/2015	93	31	N/A	40	N/A
9/30/2015	85	28	N/A	39	N/A
6/30/2015	84	25	N/A	37	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ANIK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ANIK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ANIK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ANIK 의 수익(연간 5.2%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: ANIK 의 수익(연간 5.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ANIK의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/22 12:18
종가	2026/05/22 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Anika Therapeutics, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Michael Petusky	Barrington Research Associates, Inc.
Anderson Schock	B. Riley Securities, Inc.
Mark Landy	Northland Capital Markets

Anika Therapeutics 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Anika Therapeutics, Inc. Maintains Earnings Guidance for Fiscal Year 2026

Price target increased by 9.4% to US$17.50

Anika Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2026

Consensus EPS estimates fall by 77%

Price target decreased by 7.2% to US$21.33

Price target increased by 14% to US$34.50

Recent updates

President recently bought US$150k worth of stock

Anika Therapeutics, Inc. Maintains Earnings Guidance for Fiscal Year 2026

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Bullish On Anika Therapeutics's Pullback As Integrity Scales

Anika Therapeutics, Inc., Annual General Meeting, Jun 18, 2026

Now 29% undervalued

Xilio Therapeutics, Inc. Announces Board Changes

Anika Therapeutics, Inc. to Report Q1, 2026 Results on Apr 29, 2026

Now 21% undervalued

Executive Chair exercised options and sold US$88k worth of stock

Price target increased by 9.4% to US$17.50

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2026

Anika Therapeutics, Inc. to Report Q4, 2025 Results on Feb 26, 2026

Anika Therapeutics, Inc. Announces Executive Changes

Third quarter 2025 earnings: EPS exceeds analyst expectations

Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast Cartilage Repair Scaffold and Data from U.S. Pivotal Fasttrack Phase III Study

Anika Therapeutics, Inc. to Report Q3, 2025 Results on Nov 05, 2025

Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price Following 26% Dive

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Anika Therapeutics, Inc. Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast Cartilage Repair Scaffold and Provides Program Update

Anika Therapeutics, Inc. to Report Q2, 2025 Results on Jul 30, 2025

Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell 3000 Growth Index

Consensus EPS estimates fall by 77%

Price target decreased by 7.2% to US$21.33

Revenues Working Against Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Share Price

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Anika Therapeutics, Inc., Annual General Meeting, Jun 20, 2025

Anika Therapeutics, Inc. to Report Q1, 2025 Results on May 09, 2025

Anika Therapeutics, Inc. Announces Executive Changes, Effective April 25, 2025

President exercised options and sold US$213k worth of stock

Full year 2024 earnings: EPS and revenues miss analyst expectations

Medacta Group SA (SWX:MOVE) acquired Parcus Medical, LLC from Anika Therapeutics, Inc. (NasdaqGS:ANIK).

Anika Therapeutics, Inc. to Report Q4, 2024 Results on Mar 12, 2025

Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

New major risk - Revenue and earnings growth

Anika Therapeutics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Anika Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Price target increased by 14% to US$34.50

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Anika Therapeutics, Inc. Affirms Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Anika Therapeutics, Inc. Announces Full Market Release of the Integrity Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Anika Therapeutics, Inc., Annual General Meeting, Jul 09, 2024

Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares.

Anika Therapeutics, Inc. Announces Board Changes

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Announces CFO Changes

Anika Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

President exercised options and sold US$717k worth of stock

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Anika Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Anika Therapeutics, Inc. Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Anika Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Anika Therapeutics, Inc. announces Completed Enrollment of the Pivotal Phase III Clinical Study for Hyalofast (Hyalofast 15-01) on Its Path to Achieving FDA Approval in the United States

Consensus EPS estimates fall by 39%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

President exercised options and sold US$345k worth of stock